Algerian state-owned pharmaceutical company SAIDAL has announced exceptionally strong financial results. The company’s annual revenue reached 44 billion Algerian dinars (DA), representing a remarkable 98% increase year-over-year. This surge is attributed to substantial growth in its operational results, signaling a period of significant success for the company. The announcement was made during SAIDAL’s general assembly, where the impressive financial performance was presented. Details beyond the headline figures were not provided in the initial report. This substantial growth suggests a strengthening of Algeria’s domestic pharmaceutical production capacity and potential economic benefits. The news underscores SAIDAL's increasingly prominent role within the Algerian market.